10x Genomics (TXG) Cash & Equivalents (2018 - 2026)

10x Genomics' Cash & Equivalents history runs 9 years deep, the most recent figure standing at $490.3 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 30.03% year-over-year to $490.3 million; the TTM figure through Mar 2026 stood at $490.3 million (up 30.03% YoY), while the FY2025 annual figure was $474.0 million, up 37.75% from the prior year.
• Cash & Equivalents came in at $490.3 million for Q1 2026 at 10x Genomics, up from $474.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $490.3 million in Q1 2026 to a low of $219.7 million in Q4 2022.
• A 5-year average of $354.0 million and a median of $355.8 million in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents sank 62.59% in 2022 and jumped 63.5% in 2023, its largest moves.
• 10x Genomics' Cash & Equivalents stood at $219.7 million in 2022, then jumped by 63.5% to $359.3 million in 2023, then retreated by 4.24% to $344.1 million in 2024, then surged by 37.75% to $474.0 million in 2025, then grew by 3.44% to $490.3 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $490.3 million, $474.0 million, and $432.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison